NCT01353703View on ClinicalTrials.gov

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

April 16, 2012

Primary Completion Date

February 25, 2013

Study Completion Date

February 25, 2013

Conditions
PoliomyelitisTetanusAcellular PertussisHaemophilus Influenzae Type bDiphtheriaHepatitis BDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines
Interventions
BIOLOGICAL

Infanrix hexa™

Intramuscular, three doses

Trial Locations (4)

411018

GSK Investigational Site, Pune

590010

GSK Investigational Site, Belgaun

Unknown

GSK Investigational Site, Chennai

GSK Investigational Site, Pune

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01353703 - Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine | Biotech Hunter | Biotech Hunter